Polycystic ovary syndrome (PCOS) affects 8-13% of women. Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, yet given recognised challenges, serum Anti-Müllerian Hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the life span, clustering of AMH with PCOS features, relationships to long term health outcomes, improved quality, assays standardisation and sample handling, all needed to determine cutoffs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis

No abstract

These findings suggest that I-BMS intervention was successful at improving the psychosocial and spiritual well-being of women undergoing their first IVF treatment cycle. This study highlights the importance of providing integrative fertility treatment that incorporates psychosocial and spiritual dimensions.

No abstract

Ovarian function seems to be impaired after laparoscopic unilateral salpingectomy at short-term assessment.